China Blood Products Industry Report, 2010-2011
  • Sep.2011
  • Hard Copy
  • USD $2,100
  • Pages:85
  • Single User License
    (PDF Unprintable)       
  • USD $2,000
  • Code: HM005
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,000
  • Hard Copy + Single User License
  • USD $2,300
      
Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human immunoglobulin (pH4) for intravenous injection and human immunoglobulin. In 2003-2010, the CAGR of blood products reached 20.3% in China, far above the global level in the same period.

Thanks to many favorable factors such as the advance of economy and technology, the acceleration of population growth and aging process as well as the people’s further recognition of blood products, China’s blood product market has seen buoyant momentum which is expected to maintain until 2015 and beyond.

Blood Product Market Scale in China, 2003-2015E (RMB bn)
 201109005.gif
Source: ResearchInChina

However, the blood products of China have always seen short supply due to limited blood plasma source. Especially, since August 2011 when 16 plasma collection stations were closed in Guizhou Province, the production of China-based blood product enterprises has been further constrained.

Accounting for five of the 16 plasma collection stations closed in Guizhou, Hualan Biological Engineering is the biggest victim of the shutdown, but it still comes out top in terms of the number of blood plasma stations (numbering 13), followed by Shanghai RAAS Blood Products and Beijing Tiantan Biological Products Corporation.

The supply shortage of blood products coupled with strained blood plasma source of leading enterprises has propelled China’s import of blood products, but, thus far, only human albumin and recombinant coagulation factor VIII are allowed to import from foreign countries.

Affected by the lower price of human albumin in foreign countries, China has long been increasing its import volume, with the proportion in 2010 reaching 48.4% (by lot release volume), up 7.2% year-on-year. In particular, Octapharma and Behring occupied the biggest chunk.

As for recombinant coagulation factor VIII, due to high price and policy restriction (it’s only allowed to use when hemophilia patients suffer serious bleeding and human coagulation factor VIII is unavailable), only products made by Bayer are allowed to be imported in China. However, considering the scarcity of human coagulation factor VIII and the increasing demand for coagulation factor VIII, the demand for recombinant coagulation factor VIII will grow further in China.
1. Overview of Blood Product Industry
1.1 Definition of Blood Product
1.2 Classification of Blood Products
1.3 Recombinant Blood Products
1.4 Blood Product Industry Chain
1.5 Features of Blood Products

2. Overview of China Blood Product Industry
2.1 Market Size
2.2 Development Status 
2.3 Supply & Demand
2.4 Market Competition 
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export

3. Blood Product Market Segments in China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (pH4) for Intravenous Injection
3.2.1 Competition Pattern
3.3 Coagulation Factor
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Competition Pattern

4. Key Manufacturers in China
4.1 Hualan Biological Engineering Ltd
4.1.1 Profile
4.1.2 Operation
4.1.3 Blood Products
4.2 Shanghai RAAS Blood Products Co., Ltd
4.2.1 Profile
4.2.2 Operation
4.2.3 Prospects and Trends
4.3 Beijing Tiantan Biological Products Co., Ltd
4.3.1 Profile
4.3.2 Operation
4.3.3 Chengdu Rongsheng Pharmaceuticals Co., Ltd
4.4 China Biologic Products, Inc
4.4.1 Profile
4.4.2 Operation
4.4.3 Shandong Taibang Biological Products Co. Ltd
4.4.4 Xi’an Huitian Blood Products Co. Ltd
4.4.5 Guiyang Qianfeng Biological Product Liability Co., Ltd.
4.5 Jiangxi Boya Biopharmaceutical Co., Ltd
4.5.1 Profile
4.5.2 Operation
4.6 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd
4.6.1 Profile
4.6.2 Operation
4.7 CNBG Shanghai Institute of Biological Products
4.7.1 Profile
4.7.2 Operation
4.7.3 Prospects
4.8 Shanxi Kangbao Biological Product Co., Ltd
4.8.1 Profile
4.8.2 Operation
4.9 Green Cross
4.9.1 Profile
4.9.2 Operation
Basic Components of Blood
Classification and Effects of Blood Products
Comparison between Gene Recombinant Blood Products and Traditional Blood Products
Categories and Comparison of Recombinant Blood Products in China and Worldwide
Blood Product Industry Chain
Blood Product Market Scale in China, 2003-2015E
Lot Release Volume of Blood Products (by Product) in China, 2007-Jul.2011
Product Structure of Blood Products in China (by Lot Release Volume), 2009-2010
Annual Plasma Volume in China, 2002-2010 
Geographical Distribution of Plasma Collection Station Resources in China, Aug.2011 
Comparison of Per Capita Usage of Blood Products between China and Developed Countries 
Market Share of Major Manufacturers of Blood Products in China, 2010
Comparison among Blood Product Manufacturing Enterprises in China by Product Line
Production of Blood Product Manufacturing Enterprises in China,
Aug.2011
Global Blood Product Market Scale, 2003-2010  
Blood Products in Overseas Countries
On-going Clinical Trial of New Indications Overseas
Global Blood Product Manufacturing Enterprises
Operation of International Blood Product Giants, 2010
Major Policies for Blood Products in China
Sales and YoY Growth Rate of Biological and Biochemical Pharmaceuticals in China, 2005-H1 2011  
Supply and Demand of Human Albumin Worldwide, 2010
Ratio of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2010
Market Share of Major Manufacturers of Domestic Human Albumin (by Lot Release Volume), 2007-2010
Market Share of Major Manufacturers of Imported Human Albumin (by Lot Release Volume), 2007-2010
Comparison between China and USA by Consumption of Human Immunoglobulin (pH4) for Intravenous Injection, 2010
Lot Release Volume and Its Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2010
Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (by Lot Release Volume), 2007-2010
Lot Release Volume and Its Growth Rate of Coagulation Factor VIII in China, 2008-2010
Market Share of Major Manufacturers of Coagulation Factor VIII in China (by Lot Release Volume), 2008-2010
Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII 
Lot Release Volume and Its Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2010
Market Share of Major Manufacturers of Hepatitis B Immunoglobulin (by Lot Release Volume), 2008-2010
Release Volume and Its Growth Rate of Human Immunoglobulin in China, 2008-2010
Major Manufacturers and Their Shares in Chinese Human Immunoglobulin Market (by  Lot Release Volume), 2008-2010
Release Volume and Its Growth Rate of Human Prothrombin Complex in China, 2008-2010
Manufacturers and Their Shares in Chinese Human Prothrombin Complex Market (by  Lot Release Volume), 2008-2010
Lot Release Volume and Its Growth Rate of Tetanus Immunoglobulin in China, 2008-2010
Market Share of Major Manufacturers in Chinese Tetanus Immunoglobulin Market (by  Lot Release Volume), 2008-2010
Lot Release Volume and Its Growth Rate of Rabies Immunoglobulin in China, 2008-2010
Market Share of Major Manufacturers in Chinese Rabies Immunoglobulin Market (by  Lot Release Volume), 2008-2010
Operating Revenue and Net Income of Hualan Biological Engineering Ltd, 2007-H1 2011  
Operating Revenue of Hualan Biological Engineering Ltd (by Sector), 2007-2010  
Gross Margin of Hualan Biological Engineering Ltd (by Product), 2007-2010
Operating Revenue of Hualan Biological Engineering Ltd (by Region), 2007-2010 
Distribution of Plasma Collection Stations of Hualan Biological Engineering Ltd, Aug.2011
Lot Release Volume of Blood Products of Hualan Biological Engineering Ltd, 2007-Jul.2011  
Proportion of Blood Products Release Volume of Hualan Biological Engineering Ltd, 2008-Jul.2011
Operating Revenue of Blood Products of Hualan Biological Engineering Ltd (by Product), 2007-2010  
Operating Revenue and Net Income of Shanghai RAAS Blood Products Co., Ltd, 2007-H1 2011  
Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2010  
Gross Margin of Shanghai RAAS Blood Products Co., Ltd (by Product), 2005-2010
Operating Revenue of Shanghai RAAS Blood Products Co., Ltd (by Region), 2008-2010  
Lot Release Volume of Blood Products of Shanghai RAAS Blood Products Co., Ltd, 2007-Jul.2011  
Proportion of Blood Products Release Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-Jul.2011
Distribution of Plasma Collection Stations of Shanghai RAAS Blood Products Co., Ltd, Aug.2011
Plasma Volume of Shanghai RAAS Blood Products Co., Ltd, 2007-2011E 
Operating Revenue and Net Income of Beijing Tiantan Biological Products Co., Ltd, 2007-Q1 2011  
Operating Revenue of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2010 
Gross Margin of Beijing Tiantan Biological Products Co., Ltd (by Product), 2007-2010
Operating Revenue of Beijing Tiantan Biological Products Co., Ltd (by Region), 2007-2010 
Operation of Chengdu Rongsheng Pharmaceuticals Co., Ltd, 2008-2009
Lot Release Volume of Blood Products of Chengdu Rongsheng Pharmaceuticals, 2007-Jul.2011
Proportion of Blood Products Release Volume of Chengdu Rongsheng Pharmaceuticals Co., Ltd, 2008-Jul.2011
Distribution of Blood Plasma Collection Stations of Chengdu Rongsheng Pharmaceuticals Co., Ltd, Aug.2011
Operating Revenue and Gross Profit of China Biologic Products, Inc, 2007-H1 2011  
Operating Revenue of Blood Products of China Biologic Products, Inc (by Product), 2007-2010 
Operating Revenue and Total Profit of Shandong Taibang Biological Products Co. Ltd, 2008-2009  
Lot Release Volume of Blood Products of Shandong Taibang Biological Products Co. Ltd, 2007-Jul.2011
Operating Revenue and Total Profit of Xi’an Huitian Blood Products Co. Ltd, 2008-2009 
Lot Release Volume of Blood Products of Xi’an Huitian Blood Products Co. Ltd, 2007-Jul.2011
Operating Revenue and Total Profit of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2008-2009 
Lot Release Volume of Blood Products of Guiyang Qianfeng Biological Product Liability Co., Ltd., 2007-Jul.2011
Operating Revenue and Net Income of Jiangxi Boya Biopharmaceutical Co., Ltd., 2008-2010 
Operating Revenue of Jiangxi Boya Biopharmaceutical Co., Ltd. (by Product), 2008-2010
Gross Margin of Jiangxi Boya Biopharmaceutical Co., Ltd. (by Product), 2008-2010
Prices Trend of Blood Products of Jiangxi Boya Biopharmaceutical by Product, 2008-2010
Plasma Volume of Plasma Collection Stations of Jiangxi Boya Biopharmaceutical, 2008-2010
Lot Release Volume of Blood Products of Jiangxi Boya Biopharmaceutical Co., Ltd., 2007-Jul.2011
R & D Investment and the Proportion in Sales of Jiangxi Boya Biopharmaceutical, 2008-2010
Blood Product R & D Projects and Progress of Jiangxi Boya Biopharmaceutical, July 2011
Operating Revenue and Total Profit of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2008-2009 
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd, 2007-Jul.2011
Operation of CNBG Shanghai Institute of Biological Products, 2008-2009
Blood Product List of CNBG Shanghai Institute of Biological Products, Jul.2011
Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2007-Jul.2011
Distribution of Plasma Collection Stations of CNBG Shanghai Institute of Biological Products, Aug.2011
Operation of Shanxi Kangbao Biological Products Co., Ltd, 2008-2009
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Products Co., Ltd, 2007-Jul.2011
Proportion of Blood Products Release Volume of Shanxi Kangbao Biological Products Co., Ltd, 2008-Jul.2011
Operation of Green Cross (China), 2008-2009
Blood Product List of Green Cross (China), Jul.2011
Lot Release Volume of Blood Products of Green Cross (China), 2007-Jul.2011

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号